All In Biotech

Drug Trial Radar · NCT00276094

A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women

Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 30 and 60 Mg Daily Doses With Placebo

Last checked: Nov 20, 2026Latest source record: Jun 28, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 826 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

826

Actual

Start

Jan 2006

Primary completion

Not stated

Study completion Dec 2007

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
Collaborators
Hormos Medical; QuatRx Pharmaceuticals
First posted
Jan 12, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.

Conditions

  • Atrophy
  • Vaginal Diseases

Interventions

  • Ospemifene 30 mgDrug

    1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).

  • Ospemifene 60 mgDrug

    1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).

  • PlaceboDrug

    1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).

  • Nonhormonal vaginal lubricantDrug

    Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom (MBS) of Vaginal DrynessTime frame: Baseline (Randomization) to Week 12
  2. Mean Change From Baseline in the MBS of Vaginal Pain Associated With Sexual ActivityTime frame: Baseline (Randomization) to Week 12
  3. Mean Change From Baseline in Vaginal pHTime frame: Baseline (Screening) to Week 12
  4. Mean Change From Baseline in Percentage of Parabasal Cells in Maturation Index of Vaginal SmearTime frame: Baseline (Screening) to Week 12
  5. Mean Change From Baseline in the Percentage of Superficial Cells in Maturation Index of Vaginal SmearTime frame: Baseline (Screening) to Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.